# Rescue of Nephrons With ALE.F02 (RENAL-F02)

> **NCT06047171** · PHASE2 · RECRUITING · sponsor: **Alentis Therapeutics AG** · enrollment: 80 (estimated)

## Conditions studied

- Glomerulonephritis Rapidly Progressive

## Interventions

- **BIOLOGICAL:** ALE.F02
- **DRUG:** Rituximab
- **DRUG:** GlucoCorticoid
- **DRUG:** Cyclophosphamid
- **DRUG:** Placebo
- **DRUG:** Immunosuppressive Agents

## Key facts

- **NCT ID:** NCT06047171
- **Lead sponsor:** Alentis Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-07
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047171, "Rescue of Nephrons With ALE.F02 (RENAL-F02)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06047171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*